Lauryn McLaughlin
Nurse Practitioner · Overland Park, KSNPI 1073235057
Payments from drug & device makers
Across 185 payments — averaging $20.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$656
- Sanofi$566
- Takeda Pharmaceuticals U.S.A., Inc.$454
- Regeneron Healthcare Solutions, Inc.$452
- GSK$273
- Amgen$240
- plus $1K from 23 others
What the payments were for
- Consulting fees$371%
- Food & beverage$3,57493%
- Education$2466%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 26 | $656 |
| Sanofi | 29 | $566 |
| Takeda Pharmaceuticals U.S.A., Inc. | 21 | $454 |
| Regeneron Healthcare Solutions, Inc. | 25 | $452 |
| GSK | 15 | $273 |
| Amgen | 13 | $240 |
| Kaleo, Inc. | 6 | $135 |
| Novartis | 6 | $128 |
| CSL Behring | 5 | $122 |
| Grifols USA, LLC | 5 | $103 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Hospira, Inc. | 5 | $88 |
| Pfizer | 4 | $81 |
| Hikma Pharmaceuticals USA | 4 | $68 |
| Genentech USA, Inc. | 3 | $49 |
| Optinose US, Inc. | 2 | $43 |
| ADMA Biomanufacturing LLC | 2 | $37 |
| Azurity Pharmaceuticals, Inc. | 2 | $37 |
| Ionis Pharmaceuticals, Inc. | 1 | $29 |
| LEO Pharma Inc. | 1 | $24 |
| Seqirus USA Inc | 1 | $22 |
| Biocryst US Sales Co., LLC | 1 | $22 |
| Blueprint Medicines Corporation | 1 | $22 |
| GC Biopharma USA, Inc. | 1 | $21 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Pharming Healthcare, Inc. | 1 | $19 |
| Merck | 1 | $16 |
| Octapharma USA, Inc. | 1 | $16 |
| Greer Laboratories, Inc. | 1 | $15 |
How this compares
$3,858 in reported general payments places this provider in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 21 | $19,779 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $10,512 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 32 | $8,229 |
| Azelastine Hcl | 57 | $2,315 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $1,138 |
| Ipratropium Bromide | 27 | $1,127 |
| Montelukast Sodium | 82 | $1,042 |
| Fluticasone Propionate | 36 | $805 |
| Famotidine | 13 | $269 |
| Prednisone | 28 | $55 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta | $273 | $19,77921 claims |
| AstraZenecaBreztri Aerosphere | $656 | $10,51212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,326 nurse practitioner providers in Kansas.
Other nurse practitioner in Overland Park
- Morteza RabiiOverland Park$88K
- Diane GonzalezOverland Park$18K
- Brenda LaneOverland Park$14K
- Katelyn FreemanOverland Park$10K
- Stephanie LeeOverland Park$9K
- Jennifer KershnerOverland Park$7K
- Kimberly NagelOverland Park$6K
- Valentina AlmarazOverland Park$6K
- Jessica FoleyOverland Park$5K
- Gary GrafTopeka$726K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.